



## Editor

Tore K Kvien

## Associate Editors

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

## Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 9.111

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.  
Register using this QR code.

## Editorial

- 477** Targeting Th2-typified immune responses to prevent immunopathology in rheumatic diseases: belittled therapeutic strategies?  
*F M Moret, T R D J Radstake, J A G van Roen*

## Viewpoint

- 480** How low to aim in rheumatoid arthritis? Learning from other disciplines  
*D Porter, J Dale, N Sattar*

## Review

- 483** Citrullination of autoantigens implicates NETosis in the induction of autoimmunity  
*N D Dwivedi, M Radic*

## Recommendation

- 492** EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update  
*J S Smolen, R Landewé, F C Breedveld, M Buch, G Burmester, M Dougados, P Emery, C Gaujoux-Viala, L Gossec, J Nam, S Ramiro, K Winthrop, M de Wit, D Alctaha, N Betteridge, J W J Bijlsma, M Boers, F Buttgerit, B Combe, M Cutolo, N Damjanov, J M W Hazes, M Kouloumas, T K Kvien, X Mariette, K Pavelka, P L C M van Riel, A Rubbert-Roth, M Scholte-Voshaar, D L Scott, T Sokka-Isler, J B Wong, D van der Heijde*

## Clinical and epidemiological research

- 510** Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis  
*C Gaujoux-Viala, J Nam, S Ramiro, R Landewé, M H Buch, J S Smolen, L Gossec*
- 516** Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis  
*J L Nam, S Ramiro, C Gaujoux-Viala, K Takase, M Leon-García, P Emery, L Gossec, R Landewé, J S Smolen, M H Buch*

- 529** Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis  
*S Ramiro, C Gaujoux-Viala, J L Nam, J S Smolen, M Buch, L Gossec, D van der Heijde, K Winthrop, R Landewé*

- 536** Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study  
*T Takeuchi, H Yamanaoka, N Ishiguro, N Miyasaka, M Mukai, T Matsubara, S Uchida, H Akama, H Kupper, V Arora, Y Tanaka*

- 544** Quantitative measurement of syndesmophyte volume and height in ankylosing spondylitis using CT  
*S Tan, J Yao, J A Flynn, L Yao, M M Ward*

- 551** Measurement invariance of the Illness Invalidation Inventory (3\*I) across language, rheumatic disease and gender  
*M B Kool, R van de Schoot, I López-Chicheri García, R Mewes, J A P Da Silva, K Vangronsveld, A A J Wismeijer, M A Lumley, H van Middendorp, J W J Bijlsma, G Crombez, W Rief, R Geenen*

- 557** Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein  
*S P Ardoin, L E Schanberg, C I Sandborg, H X Barnhart, G W Evans, E Yow, K L Mieszkański, N T Ilowite, A Eberhard, L F Imundo, Y Kimura, D Levy, E von Scheven, E Silverman, S L Bowyer, L Punaro, N G Singer, D D Sherry, D K McCurdy, M Klein-Gitelman, C Wallace, R M Silver, L Wagner-Weiner, G C Higgins, H I Brunner, L Jung, J B Soep, A M Reed, S D Thompson, for the APPLE investigators*

- 567** Clustering of hand osteoarthritis progression and its relationship to progression of osteoarthritis at the knee  
*J Bijsterbosch, I Meulenbelt, I Watt, F R Rosendaal, T W J Huizinga, M Kloppenburg*

- 573** Association between testosterone levels and risk of future rheumatoid arthritis in men: a population-based case-control study  
*M Pikwer, A Giwercman, U Bergström, J-Å Nilsson, L T H Jacobsson, C Turesson*

- 580** The autoantibody repertoire in periodontitis: a role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis?  
*P de Pablo, T Dietrich, I L C Chapple, M Milward, M Chowdhury, P J Charles, C D Buckley, P J Venables*

- 587** Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial  
*F Huang, J Gu, P Zhu, C Bao, J Xu, H Xu, H Wu, G Wang, Q Shi, N Andhivarathai, J Anderson, A L Pangan*

- 595** Biologic discontinuation studies: a systematic review of methods  
*K Yoshida, Y-K Sung, A Kavanaugh, S-C Bae, M E Weinblatt, M Kishimoto, K Matsui, S Tohma, D H Solomon*

## Basic and translational research

- 600** The histamine H<sub>4</sub> receptor mediates inflammation and Th17 responses in preclinical models of arthritis  
*J M Cowden, F Yu, H Banie, M Farahani, P Ling, S Nguyen, J P Riley, M Zhang, J Zhu, P J Dunford, R L Thurmond*

## MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)



When you have finished with this please recycle it

**609** Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus  
*N Ronda, E Favari, M O Borghi, F Ingegnoli, M Gerosa, C Chighizola, F Zimetti, M P Adorni, F Bernini, P L Meroni*

**616** Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis  
*M Corbera-Bellalta, A García-Martínez, E Lozano, E Planas-Rigol, I Tavera-Bahillo, M A Alba, S Prieto-González, M Bujosa, G Espigol-Frigolé, J Hernández-Rodríguez, P L Fernández, P Roux-Lombard, J-M Dayer, M U Rahman, M C Cid*

**624** Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling  
*A Distler, C Ziemer, C Beyer, N-Y Lin, C-W Chen, K Palumbo-Zerr, C Dees, A Weidemann, O Distler, G Schett, J H W Distler*

## Letters

**628** Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries  
*J Zavada, W G Dixon, J Askling, for the EULAR Study group on Longitudinal Observational Registers and Drug Studies*

**629** No evidence for a critical role of the unfolded protein response in synovium and blood of patients with ankylosing spondylitis  
*B Neerincx, S Carter, R J Lories*

**631** Differential expression of adipokines in infrapatellar fat pad (IPFP) and synovium of osteoarthritis patients and healthy individuals  
*J Conde, M Scotece, V López, V Abella, M Hermida, J Pino, F Lago, J J Gómez-Reino, O Gualillo*

**633** HLA-B60 and the HLA-B27/HLA-B60 genotype are not risk factors for acute anterior uveitis  
*F A van Gaalen, W Verduijn, D L Roelen, T W J Huizinga, D van der Heijde, R E M Toes*

## Electronic pages

**e10** Detection of antinuclear antibodies: added value of solid phase assay?  
*X Bossuyt, S Fieeuws*

**e11** Response to: 'Detection of antinuclear antibodies: added-value of solid phase assay?' by Bossuyt and Fieeuws  
*N Agnon-Levin, J Damoiseaux, Y Shoenfeld*

**e12** Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss; EGPA): to use or not to use?  
*S Moiseev, P Novikov*

**e13** Response to: 'Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss; EGPA): to use or not to use?' by Moiseev and Novikov  
*M Samson, L Guillevin*

**e14** Comorbidities in a Mexican mestizo cohort with established rheumatoid arthritis  
*D Vega-Morales, M Barrón-Almazán, A Arana-Guajardo*

**e15** Response to: 'Comorbidities in a Mexican mestizo cohort with established rheumatoid arthritis' by Vega-Morales *et al*  
*M Dougados*